Ebrotidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ebrotidine
Ebrotidine.png
Systematic (IUPAC) name
N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide
Clinical data
Legal status
?
Routes Oral
Identifiers
CAS number 100981-43-9 YesY
ATC code ?
PubChem CID 65869
ChemSpider 59279 N
UNII TMZ3IBW2OW YesY
Chemical data
Formula C14H17BrN6O2S3 
Mol. mass 477.42 g/mol
 N (what is this?)  (verify)

Ebrotidine is an H2 receptor antagonist with gastroprotective activity against ethanol-, aspirin- or stress-induced gastric mucosal damage.[1] The antisecretory properties of ebrotidine are similar to those of ranitidine, and approximately 10-fold greater than those of cimetidine. Ebrotidine has anti-Helicobacter pylori activity via inhibition of the urease enzyme and the proteolytic and mucolytic activities of the bacterium. However, its activity is synergistic with a number of antibacterial agents. Ebrotidine counteracts the inhibitory effects of H. pylori lipo-polysaccharides.

Ebrotidine has been shown to be as effective as ranitidine for the treatment of gastric or duodenal ulcers or erosive reflux oesophagitis, with significantly better ulcer healing rates (albeit inexplicably) in those who smoke.[1]

References[edit]

  1. ^ a b Patel SS, Wilde MI (Jun 1996). "Ebrotidine". Drugs 51 (6): 974–980. doi:10.2165/00003495-199651060-00006. PMID 8736619.